Clinical Implications of Stenotrophomonas maltophilia Resistant to Trimethoprim-Sulfamethoxazole: a Study of 69 Patients at 2 University Hospitals

REFERENCES

• Gold HS, Moellering RC, Jr. Antimicrobial-drug resistance. N Engl J Med 1996; 335: 1445–53.
   PubMed Web of Science ®Google Scholar
• Smith TL, Pearson ML, Wilcox KR, Cruz C, Lancaster MV, Robinson-Dunn B, et al. Emergence of vancomycin resistance in Staphylococcus aureus. Glycopeptide-Intermediate Staphylococcus aureus Working Group. N Engl J Med 1999; 340: 493–501.
   Google Scholar
• Gilardi GL. Pseudomonas maltophilia infections in man. Am J Clin Pathol 1969; 51: 58–61.
   PubMed Web of Science ®Google Scholar
• Quinn JP. Clinical problems posed by multiresistant nonfermenting gram-negative pathogens. Clin Infect Dis 1998; 27 (Suppl 1): S117–24.
   PubMed Web of Science ®Google Scholar
• Khardori N, Elting L, Wong E, Schable B, Bodey GP. Nosocomial infections due to Xanthomonas maltophilia (Pseudomonas maltophilia) in patients with cancer. Rev Infect Dis 1990; 12: 997–1003.
   Google Scholar
• Denton M, Kerr KG. Microbiological and clinical aspects of infection associated with Stenotrophomonas maltophilia. Clin Microbiol Rev 1998; 11: 57–80.
   PubMed Web of Science ®Google Scholar
• Carroll KC, Cohen S, Nelson R, Campbell DM, Claridge JD, Garrison MW, et al. Comparison of various in vitro susceptibility methods for testing Stenotrophomonas maltophilia. Diagn Microbiol Infect Dis 1998; 32: 229–35.
   PubMed Web of Science ®Google Scholar
• Vartivarian SE, Papadakis KA, Palacios JA, Manning JT, Jr, Anaissie EJ. Mucocutaneous and soft tissue infections caused by Xanthomonas maltophilia. A new spectrum. Ann Intern Med 1994; 121: 969–73.
   PubMed Web of Science ®Google Scholar
• Muder RR, Harris AP, Muller S, Edmond M, Chow JW, Papadakis K, et al. Bacteremia due to Stenotrophomonas (Xanthomonas) maltophilia: a prospective, multicenter study of 91 episodes. Clin Infect Dis 1996; 22: 508–12.
   PubMed Web of Science ®Google Scholar
• Penzak SR, Abate BJ. Stenotrophomonas (Xanthomonas) maltophilia: a multidrug-resistant nosocomial pathogen. Pharmacotherapy 1997; 17: 293–301.
   PubMed Web of Science ®Google Scholar
• National Committee for Clinical Laboratory Standards. Performance standards for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. Approved standard M100-S8 NCCLS, Villanova, PA (1998).
   Google Scholar
• McCabe WR, Jackson GG. Gram-negative bacteremia I. Etiology and ecology. Arch Intern Med 1962; 110: 847–55.
   Web of Science ®Google Scholar
• Garner JS, Jarvis WR, Emori TG, Toran TC, Hughes JM. CDC definitions for nosocomial infections. Am J Infect Control 1988; 16: 128–40.
   PubMed Web of Science ®Google Scholar
• Bone RC, Balk RA, Cerra FB, Dellinger RP, Fein AM, Knaus WA, et al. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Chest 1992; 101: 1644–55.
   PubMed Web of Science ®Google Scholar
• Pittet D, Harbarth S, Suter PM, Reinhart K, Leighton A, Barker C, et al. Impact of immunomodulating therapy on morbidity in patients with severe sepsis. Am J Respir Crit Care Med 1999; 160: 852–7.
   PubMed Web of Science ®Google Scholar
• Townsend TR, Shapiro M, Rosner B, Kass EH. Use of antimicrobial drugs in general hospitals. I. Description of population and definition of methods. J Infect Dis 1979; 139: 688–97.
   Google Scholar
• Jaccard C, Troillet N, Harbarth S, Zanetti G, Aymon D, Schneider R, et al. Prospective randomized comparison of imipenem–cilastatin and piperacillin–tazobactam in nosocomial pneumonia or peritonitis. Antimicrob Agents Chemother 1998; 42: 2966–72.
   PubMed Web of Science ®Google Scholar
• Harbarth S, Rutschmann O, Sudre P, Pittet D. Impact of methicillin resistance on the outcome of patients with bacteremia caused by Staphylococcus aureus. Arch Intern Med 1998; 158: 182–9.
   PubMed Web of Science ®Google Scholar
• Gardner P, Griffin WB, Swartz MN, Kunz LJ. Nonfermentative gram-negative bacilli of nosocomial interest. Am J Med 1970; 48: 735–49.
   PubMed Web of Science ®Google Scholar
• Zuravleff JJ, Yu VL. Infections caused by Pseudomonas maltophilia with emphasis on bacteremia: case reports and a review of the literature. Rev Infect Dis 1982; 4: 1236–46.
   PubMedGoogle Scholar
• Elting LS, Bodey GP. Septicemia due to Xanthomonas species and non-aeruginosa Pseudomonas species: increasing incidence of catheter–related infections. Medicine (Baltimore) 1990; 69: 296–306.
   PubMed Web of Science ®Google Scholar
• Victor MA, Arpi M, Bruun B, Jonsson V, Hansen MM. Xanthomonas maltophilia bacteremia in immunocompromised hematological patients. Scand J Infect Dis 1994; 26: 163–70.
   Google Scholar
• Laing FP, Ramotar K, Read RR, Alfieri N, Kureishi A, Henderson EA, Louie TJ. Molecular epidemiology of Xanthomonas maltophilia colonization and infection in the hospital environment. J Clin Microbiol 1995; 33: 513–8.
   Google Scholar
• Carmeli Y, Samore MH. Comparison of treatment with imipenem vs. ceftazidime as a predisposing factor for nosocomial acquisition of Stenotrophomonas maltophilia: a historical cohort study. Clin Infect Dis 1997; 24: 1131–4.
   Google Scholar
• Vartivarian S, Anaissie E, Bodey G, Sprigg H, Rolston K. A changing pattern of susceptibility of Xanthomonas maltophilia to antimicrobial agents: implications for therapy. Antimicrob Agents Chemother 1994; 38: 624–7.
   PubMed Web of Science ®Google Scholar
• Holmes B, Lapage SP, Easterling BG. Distribution in clinical material and identification of Pseudomonas maltophilia. J Clin Pathol 1979; 32: 66–72.
   Google Scholar
• Hulisz DT, File TM. Predisposing factors and antibiotic use in nosocomial infections caused by Xanthomonas maltophilia. Infect Control Hosp Epidemiol 1992; 13: 489–90.
   PubMed Web of Science ®Google Scholar
• Morrison AJ, Jr, Hoffmann KK, Wenzel RP. Associated mortality and clinical characteristics of nosocomial Pseudomonas maltophilia in a university hospital. J Clin Microbiol 1986; 24: 52–5.
   PubMed Web of Science ®Google Scholar
• Villarino ME, Stevens LE, Schable B, Mayers G, Miller JM, Burke JP, Jarvis WR. Risk factors for epidemic Xanthomonas maltophilia infection/colonization in intensive care unit patients. Infect Control Hosp Epidemiol 1992; 13: 201–6.
   Google Scholar
• Fang FC, Madinger NE. Resistant nosocomial gram-negative bacillary pathogens: Acinetobacter baumannii, Xanthomonas maltophilia, and Pseudomonas cepacia. Curr Clin Top Infect Dis 1996; 16: 52–83.
   PubMedGoogle Scholar
• Jang TN, Wang FD, Wang LS, Liu CY, Liu IM. Xanthomonas maltophilia bacteremia: an analysis of 32 cases. J Formos Med Assoc 1992; 91: 1170–6.
   Google Scholar
• Vartivarian SE, Papadakis KA, Anaissie EJ. Stenotrophomonas (Xanthomonas) maltophilia urinary tract infection. A disease that is usually severe and complicated. Arch Intern Med 1996; 156: 433–5.
   Google Scholar
• Papadakis KA, Vartivarian SE, Vassilaki ME, Anaissie EJ. Stenotrophomonas maltophilia meningitis. Report of two cases and review of the literature. J Neurosurg 1997; 87: 106–8.
   PubMed Web of Science ®Google Scholar
• Caputo GM, Cavanagh PR, Ulbrecht JS, Gibbons GW, Karchmer AW. Assessment and management of foot disease in patients with diabetes. N Engl J Med 1994; 331: 854–60.
   Google Scholar